An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas

.

Source: Expert Opinion on Biological Therapy - February 2, 2024 Category: Drugs & Pharmacology Authors: Kamila PolgarovaMarek Trnenya First Department of Internal Medicine-Hematology, General University Hospital, Prague, Czech Republicb First Medicine, Charles University, Prague, Czech Republic Source Type: research